Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Tuesday, November 3, 2026

Back to today

Stevanato down 30%. Yikes.

Stevanato fell 30% after forecasting low-single-digit 2027 growth as lower Nexa syringe volumes from a GLP-1 customer offset solid Q3 margins and non-GLP biologics demand.

STVN $3.6B
Best Anchor Stocks 3 clicks

From X

@Fierce__beast 1 click

Fierce_beast on X

$EVLV i'm getting something like -.2/sh of real earnigns right now, and something in that ball park for next year as a base case. The downside is significant PT <3/sh if they are unable to grow into their margins, or face continuous pressure from opengate. If they succeed (let's say 25% growth and margin improvement), i also see limited upside: Here's how i get my Earnings number: Adj. EBITDA: +$15M Stock comp: -$23M Fleet wear (D&A + retired units): -$29M Interest, growth capex, net one-offs: -$3M earnings of about -$40M, or -$0.20/sh Current management missed 3 of 4 gross margin guides, and the promised shift toward subscription reversed twice. Recent trends: Revenue +34%, but ARR only +20% (was 34% five quarters ago). Backlog (RPO) up only mid-teens Gross margin 58% → 50% in two years New ARR per unit added: ~$17K in 2024 → ~$10K now Here's how i get limited upside in the bull case: revenue grow 25% a year to about $557M in 2031 adj. EBITDA margin rises from 8.5% to 25% by 2031, then 27% by terminal year 2040 or so. SBC falls to 5–7% of revenue and fleet wear to 10–12%; Assuming a 9% required return, i am getting around 4.5/sh which is the current stock price. Are they subscale? Don't they have like 9k units deployed? That's subscale? What exactly are the "scale" advantages for this type of company? How good is their product vs opengate as a total cost of ownership? doesn't look good for evolv. Says Evolv is 5x the price over 4 years but little differentiation in terms of throughput and accuracy. Why would anyone buy evolv. The school contracts covered by the FTC settlement date from April 2022 through June 2023, and on 4-year terms they renew in 2026–27. We will just see what happens thousands of units are up for renewal or if there is some switching that happens.
@calvinblissett

Calvin Blissett on X

I listened to all Whitney Wolfe Heard interviews, that gave me a lot of confidence she would/will improve the consumer experience relentlessly, the business wasn’t/isn’t declining as much as perceived or sentiment makes it out to be. Even if it continued melting at the current pace and never growing the FCF would create immense value for equity holders. I don’t think it will continue melting though as they update and iterate on the experience and resume marketing spend. I think resuming marketing spend would be a big catalyst in terms of returning to growth that wasn’t reflected in the stock . $BMBL

Investor Letters

All letters

When the liquidity does not add up

Arbor Realty Trust’s dividend suspension is presented as creating $60 million of liquidity, raising questions about its ability to meet…

ABR $2.2B
John Hempton's Newsletter 3 clicks

Verra veerer

Verra Mobility’s Avis termination threatens 2027 earnings, while Government Solutions profit rose 25% and implied fourth-quarter guidance…

VRRM $404M
The Oak Bloke 3 clicks
PRIM · long

Primoris Services CORP

Primoris Services, a $5 billion EPC contractor, has fallen about 60% from its peak.

PRIM $3.9B
Value Investors Club

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 74 of 274

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

338 firms

Sectors

Ordered by how often our editor reaches for them.